How Histone Deacetylase Inhibitors Help Fight Neuroblastoma
Author Information
Author(s): Annick Mühlethaler-Mottet, Roland Meier, Marjorie Flahaut, Katia Balmas Bourloud, Katya Nardou, Jean-Marc Joseph, Nicole Gross
Primary Institution: University Hospital CHUV, Lausanne, Switzerland
Hypothesis
Histone deacetylase inhibitors (HDACi) can induce cell death in neuroblastoma cells through specific molecular mechanisms.
Conclusion
HDACi are effective anti-tumour agents for neuroblastoma, reducing cell viability and potentially decreasing angiogenesis by lowering VEGF production.
Supporting Evidence
- HDACi like Sodium Butyrate, SAHA, and TSA significantly reduce neuroblastoma cell viability.
- These HDACi induce cell cycle arrest in the G2/M phase and activate the intrinsic apoptotic pathway.
- HDACi decrease the secretion of VEGF, which is important for tumor growth and blood vessel formation.
Takeaway
This study shows that certain drugs can help kill cancer cells in kids by making them stop growing and die, which is good for treating a tough type of cancer called neuroblastoma.
Methodology
The study involved treating neuroblastoma cell lines with HDACi and analyzing their effects on cell viability, cell cycle progression, and apoptosis through various assays.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website